首页 > 最新文献

The Milbank Quarterly最新文献

英文 中文
A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders 国际药品价格谈判框架的比较分析:主要利益相关者访谈研究
Pub Date : 2024-09-18 DOI: 10.1111/1468-0009.12714
ISELIN DAHLEN SYVERSEN, KEVIN SCHULMAN, AARON S. KESSELHEIM, WILLIAM B. FELDMAN
Policy Points Health care systems around the world rely on a range of methods to ensure the affordability of prescription drugs, including negotiating prices soon after drug approval and relying on formal clinical assessments that compare newly approved therapies with existing alternatives. The negotiation framework established under the Inflation Reduction Act is far more limited than other frameworks explored in this study. Adding elements from these frameworks could lead to more effective price negotiation in the United States. ContextIn 2022, Congress passed the Inflation Reduction Act, which allowed Medicare, for the first time, to begin negotiating the prices for certain high‐cost brand‐name prescription drugs. Many other industrialized countries negotiate drug prices, and we sought to compare and contrast key features of the negotiation process across several health systems. We focused, in particular, on the criteria for selecting drugs for price negotiation, procedures for negotiation, factors that influence negotiated prices, and how prices are implemented.MethodsWe included four G7 countries in our analysis (Canada, France, Germany, and the United Kingdom [England]), two Benelux countries (Belgium and the Netherlands), and one Scandinavian country (Norway) with long‐established frameworks for drug price negotiation. We also analyzed the Veterans Affairs Health System in the United States. For each system, we gathered relevant legislation, government publications, and guidelines to understand negotiation frameworks, and we reached out to key drug price negotiators in each system to conduct semistructured interviews. All interviews were recorded, transcribed, and coded, and data were analyzed based on an internal assessment tool that we developed.FindingsAll eight systems negotiate the prices of brand‐name prescription drugs soon after approval and rely on formal clinical assessments that compare newly approved drugs with existing therapies. Systems in our study differed on characteristics such as whether the body performing clinical assessments is separate from the negotiating authority, how added health benefit is assessed, whether explicit willingness‐to‐pay thresholds are employed, and how specific approaches for priority disease areas are taken.ConclusionsHigh‐income countries around the world adopt different approaches to conducting price negotiations on brand‐name drugs but coalesce around a set of practices that will largely be absent from the current Medicare negotiation framework. US policymakers might consider adding some of these characteristics in the future to improve negotiation outcomes.
政策要点 世界各地的医疗保健系统都依靠一系列方法来确保处方药的可负担性,包括在药品批准后不久就进行价格谈判,以及依靠正式的临床评估将新批准的疗法与现有的替代疗法进行比较。与本研究探讨的其他框架相比,根据《降低通货膨胀法》建立的谈判框架要有限得多。加入这些框架中的元素可以使美国的价格谈判更加有效。背景2022 年,美国国会通过了《通货膨胀削减法》,首次允许医疗保险开始对某些高价品牌处方药进行价格谈判。许多其他工业化国家也在进行药品价格谈判,我们试图比较和对比几个医疗系统谈判过程的主要特点。我们的分析包括四个七国集团国家(加拿大、法国、德国和英国)、两个比荷卢国家(比利时和荷兰)和一个斯堪的纳维亚国家(挪威),这些国家的药品价格谈判框架由来已久。我们还分析了美国退伍军人事务卫生系统。对于每个系统,我们都收集了相关立法、政府出版物和指南,以了解谈判框架,并与每个系统的主要药品价格谈判人员进行了半结构化访谈。我们对所有访谈进行了记录、转录和编码,并根据我们开发的内部评估工具对数据进行了分析。研究结果所有八个系统都是在品牌处方药获得批准后不久进行价格谈判,并依赖于正式的临床评估,将新批准的药物与现有疗法进行比较。在我们的研究中,各系统的特点各不相同,如进行临床评估的机构是否独立于谈判机构,如何评估额外的健康益处,是否采用了明确的支付意愿阈值,以及如何针对重点疾病领域采取特定的方法。美国的政策制定者可以考虑在未来增加其中的一些特点,以改善谈判结果。
{"title":"A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders","authors":"ISELIN DAHLEN SYVERSEN, KEVIN SCHULMAN, AARON S. KESSELHEIM, WILLIAM B. FELDMAN","doi":"10.1111/1468-0009.12714","DOIUrl":"https://doi.org/10.1111/1468-0009.12714","url":null,"abstract":"<jats:label/><jats:boxed-text content-type=\"box\" position=\"anchor\"><jats:caption>Policy Points</jats:caption><jats:list list-type=\"bullet\"> <jats:list-item>Health care systems around the world rely on a range of methods to ensure the affordability of prescription drugs, including negotiating prices soon after drug approval and relying on formal clinical assessments that compare newly approved therapies with existing alternatives.</jats:list-item> <jats:list-item>The negotiation framework established under the Inflation Reduction Act is far more limited than other frameworks explored in this study. Adding elements from these frameworks could lead to more effective price negotiation in the United States.</jats:list-item> </jats:list></jats:boxed-text>ContextIn 2022, Congress passed the Inflation Reduction Act, which allowed Medicare, for the first time, to begin negotiating the prices for certain high‐cost brand‐name prescription drugs. Many other industrialized countries negotiate drug prices, and we sought to compare and contrast key features of the negotiation process across several health systems. We focused, in particular, on the criteria for selecting drugs for price negotiation, procedures for negotiation, factors that influence negotiated prices, and how prices are implemented.MethodsWe included four G7 countries in our analysis (Canada, France, Germany, and the United Kingdom [England]), two Benelux countries (Belgium and the Netherlands), and one Scandinavian country (Norway) with long‐established frameworks for drug price negotiation. We also analyzed the Veterans Affairs Health System in the United States. For each system, we gathered relevant legislation, government publications, and guidelines to understand negotiation frameworks, and we reached out to key drug price negotiators in each system to conduct semistructured interviews. All interviews were recorded, transcribed, and coded, and data were analyzed based on an internal assessment tool that we developed.FindingsAll eight systems negotiate the prices of brand‐name prescription drugs soon after approval and rely on formal clinical assessments that compare newly approved drugs with existing therapies. Systems in our study differed on characteristics such as whether the body performing clinical assessments is separate from the negotiating authority, how added health benefit is assessed, whether explicit willingness‐to‐pay thresholds are employed, and how specific approaches for priority disease areas are taken.ConclusionsHigh‐income countries around the world adopt different approaches to conducting price negotiations on brand‐name drugs but coalesce around a set of practices that will largely be absent from the current Medicare negotiation framework. US policymakers might consider adding some of these characteristics in the future to improve negotiation outcomes.","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In the September 2024 Issue of the Quarterly 在《季刊》2024 年 9 月刊中
Pub Date : 2024-09-17 DOI: 10.1111/1468-0009.12716
ALAN B. COHEN
{"title":"In the September 2024 Issue of the Quarterly","authors":"ALAN B. COHEN","doi":"10.1111/1468-0009.12716","DOIUrl":"https://doi.org/10.1111/1468-0009.12716","url":null,"abstract":"","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success 孤儿药法案》40 周年:立法的胜利与成功的挑战
Pub Date : 2023-12-12 DOI: 10.1111/1468-0009.12680
PETER SALTONSTALL, HEIDI ROSS, PAUL T. KIM

Policy Points

  • The Orphan Drug Act (ODA) was the result of patient advocacy and by many measures has been strikingly successful. However, approximately 95% of the more than 7,000 known rare diseases still have no US Food and Drug Administration–approved treatment.
  • The ODA's success led to sustained criticism of high drug prices, often for products that have orphan drug indications. Critics misconstrue the ODA's intent and propose reducing its incentives instead of pursuing policies focused on addressing broader prescription drug price challenges that exist in both the orphan and nonorphan drug market.
  • Patients and their families will continue to defend the purpose and integrity of the ODA and to drive investments into rare disease research and clinical development.

政策要点《孤儿药法案》(ODA)是患者倡导的结果,从许多方面来看都取得了巨大成功。然而,在已知的 7,000 多种罕见病中,仍有约 95% 的罕见病没有得到美国食品药品管理局批准的治疗方法。ODA 的成功导致了对高药价的持续批评,而高药价往往是针对孤儿药适应症产品的。批评者曲解了 ODA 的初衷,并建议减少其激励措施,而不是推行侧重于解决孤儿药和非孤儿药市场中存在的更广泛的处方药价格挑战的政策。患者及其家属将继续捍卫 ODA 的宗旨和完整性,并推动对罕见病研究和临床开发的投资。
{"title":"The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success","authors":"PETER SALTONSTALL, HEIDI ROSS, PAUL T. KIM","doi":"10.1111/1468-0009.12680","DOIUrl":"https://doi.org/10.1111/1468-0009.12680","url":null,"abstract":"<div>\u0000<div>\u0000<h3>Policy Points</h3>\u0000<p>\u0000</p><ul>\u0000<li>The Orphan Drug Act (ODA) was the result of patient advocacy and by many measures has been strikingly successful. However, approximately 95% of the more than 7,000 known rare diseases still have no US Food and Drug Administration–approved treatment.</li>\u0000<li>The ODA's success led to sustained criticism of high drug prices, often for products that have orphan drug indications. Critics misconstrue the ODA's intent and propose reducing its incentives instead of pursuing policies focused on addressing broader prescription drug price challenges that exist in both the orphan and nonorphan drug market.</li>\u0000<li>Patients and their families will continue to defend the purpose and integrity of the ODA and to drive investments into rare disease research and clinical development.</li>\u0000</ul><p></p></div>\u0000</div>","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138693355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life Satisfaction and Subsequent Physical, Behavioral, and Psychosocial Health in Older Adults. 老年人的生活满意度与随后的身体、行为和心理健康。
IF 6.6 Pub Date : 2021-03-01 Epub Date: 2021-02-02 DOI: 10.1111/1468-0009.12497
Eric S Kim, Scott W Delaney, Louis Tay, Ying Chen, E D Diener, Tyler J Vanderweele

Policy Points Several intergovernmental organizations (Organisation for Economic Co-operation and Development, World Health Organization, United Nations) are urging countries to use well-being indicators (e.g., life satisfaction) in addition to traditional economic indicators when making important policy decisions. As the number of governments implementing this new approach grows, so does the need to continue evaluating the health and well-being outcomes we might observe from policies aimed at improving life satisfaction. The results of this study suggest that life satisfaction is a valuable target for policies aiming to enhance several indicators of psychosocial well-being, health behaviors, and physical health outcomes.

Context: Several intergovernmental organizations (Organisation for Economic Co-operation and Development, World Health Organization, United Nations) are urging countries to use well-being indicators (e.g., life satisfaction) in addition to traditional economic indicators when making important policy decisions. As the number of governments implementing this new approach grows, so does the need to continue evaluating the health and well-being outcomes we might observe from policies aimed at improving life satisfaction.

Methods: We evaluated whether positive change in life satisfaction (between t0 ;2006/2008 and t1 ;2010/2012) was associated with better outcomes on 35 indicators of physical, behavioral, and psychosocial health and well-being (in t2 ;2014/2016). Data were from 12,998 participants in the University of Michigan's Health and Retirement Study-a prospective and nationally representative cohort of US adults over age 50.

Findings: Participants with the highest (versus lowest) life satisfaction had better subsequent outcomes on some physical health indicators (lower risk of pain, physical functioning limitations, and mortality; lower number of chronic conditions; and higher self-rated health) and health behaviors (lower risk of sleep problems and more frequent physical activity), and nearly all psychosocial indicators (higher positive affect, optimism, purpose in life, mastery, health mastery, financial mastery, and likelihood of living with spouse/partner; and lower depression, depressive symptoms, hopelessness, negative affect, perceived constraints, and loneliness) over the 4-year follow-up period. However, life satisfaction was not subsequently associated with many specific health conditions (i.e., diabetes, hypertension, stroke, cancer, heart disease, lung disease, arthritis, overweight/obesity, or cognitive impairment), other health behaviors (i.e., binge drinking or smoking), or frequency of contact with children, family, or friends.

Conclusions: These results suggest that life satisfaction is a valuable target for policies aiming to enhance several indicators of psychosocial well-being,

若干政府间组织(经济合作与发展组织、世界卫生组织、联合国)正在敦促各国在作出重要政策决定时,除使用传统经济指标外,还使用福祉指标(如生活满意度)。随着实施这种新方法的政府越来越多,我们也有必要继续评估旨在提高生活满意度的政策对健康和福祉的影响。本研究的结果表明,生活满意度是一个有价值的政策目标,旨在提高社会心理健康、健康行为和身体健康结果的几个指标。背景:几个政府间组织(经济合作与发展组织、世界卫生组织、联合国)正在敦促各国在作出重要政策决定时,除传统经济指标外,还使用福祉指标(如生活满意度)。随着实施这种新方法的政府越来越多,我们也有必要继续评估旨在提高生活满意度的政策对健康和福祉的影响。方法:我们评估了生活满意度的积极变化(2006/2008年至2010/2012年)是否与35项身体、行为和心理健康和福祉指标的更好结果相关(t2;2014/2016年)。数据来自密歇根大学健康与退休研究的12998名参与者,这是一项前瞻性的、具有全国代表性的50岁以上美国成年人队列研究。研究结果:生活满意度最高(相对于最低)的参与者在一些身体健康指标上有更好的后续结果(更低的疼痛风险、身体功能限制和死亡率;慢性病人数较少;更高的自我评价健康)和健康行为(更低的睡眠问题风险和更频繁的身体活动),以及几乎所有的社会心理指标(更高的积极影响,乐观,生活目标,掌握,健康掌握,财务掌握,以及与配偶/伴侣生活的可能性;在4年的随访期间,抑郁、抑郁症状、绝望、负面影响、感知约束和孤独感更低。然而,生活满意度随后与许多特定的健康状况(即糖尿病、高血压、中风、癌症、心脏病、肺病、关节炎、超重/肥胖或认知障碍)、其他健康行为(即酗酒或吸烟)或与儿童、家人或朋友接触的频率无关。结论:这些结果表明,生活满意度对于旨在提高社会心理健康、健康行为和身体健康结果等指标的政策来说是一个有价值的目标。
{"title":"Life Satisfaction and Subsequent Physical, Behavioral, and Psychosocial Health in Older Adults.","authors":"Eric S Kim,&nbsp;Scott W Delaney,&nbsp;Louis Tay,&nbsp;Ying Chen,&nbsp;E D Diener,&nbsp;Tyler J Vanderweele","doi":"10.1111/1468-0009.12497","DOIUrl":"https://doi.org/10.1111/1468-0009.12497","url":null,"abstract":"<p><p>Policy Points Several intergovernmental organizations (Organisation for Economic Co-operation and Development, World Health Organization, United Nations) are urging countries to use well-being indicators (e.g., life satisfaction) in addition to traditional economic indicators when making important policy decisions. As the number of governments implementing this new approach grows, so does the need to continue evaluating the health and well-being outcomes we might observe from policies aimed at improving life satisfaction. The results of this study suggest that life satisfaction is a valuable target for policies aiming to enhance several indicators of psychosocial well-being, health behaviors, and physical health outcomes.</p><p><strong>Context: </strong>Several intergovernmental organizations (Organisation for Economic Co-operation and Development, World Health Organization, United Nations) are urging countries to use well-being indicators (e.g., life satisfaction) in addition to traditional economic indicators when making important policy decisions. As the number of governments implementing this new approach grows, so does the need to continue evaluating the health and well-being outcomes we might observe from policies aimed at improving life satisfaction.</p><p><strong>Methods: </strong>We evaluated whether positive change in life satisfaction (between t<sub>0</sub> ;2006/2008 and t<sub>1</sub> ;2010/2012) was associated with better outcomes on 35 indicators of physical, behavioral, and psychosocial health and well-being (in t<sub>2</sub> ;2014/2016). Data were from 12,998 participants in the University of Michigan's Health and Retirement Study-a prospective and nationally representative cohort of US adults over age 50.</p><p><strong>Findings: </strong>Participants with the highest (versus lowest) life satisfaction had better subsequent outcomes on some physical health indicators (lower risk of pain, physical functioning limitations, and mortality; lower number of chronic conditions; and higher self-rated health) and health behaviors (lower risk of sleep problems and more frequent physical activity), and nearly all psychosocial indicators (higher positive affect, optimism, purpose in life, mastery, health mastery, financial mastery, and likelihood of living with spouse/partner; and lower depression, depressive symptoms, hopelessness, negative affect, perceived constraints, and loneliness) over the 4-year follow-up period. However, life satisfaction was not subsequently associated with many specific health conditions (i.e., diabetes, hypertension, stroke, cancer, heart disease, lung disease, arthritis, overweight/obesity, or cognitive impairment), other health behaviors (i.e., binge drinking or smoking), or frequency of contact with children, family, or friends.</p><p><strong>Conclusions: </strong>These results suggest that life satisfaction is a valuable target for policies aiming to enhance several indicators of psychosocial well-being, ","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":" ","pages":"209-239"},"PeriodicalIF":6.6,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/1468-0009.12497","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25321360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 64
In the March 2021 Issue of the Quarterly. 《季刊》2021年3月刊。
IF 6.6 Pub Date : 2021-03-01 DOI: 10.1111/1468-0009.12512
Alan B Cohen
Since the launch of the Quarterly’s Building Back Better series of policy opinion posts in November 2020, the United States has experienced one of the most tumultuous and traumatic periods in its history. In fact, the entire year of 2020 will be remembered as a “perfect storm” of global pandemic, tragically avoidable death, reduced life expectancy, economic depression, racial injustice, and civil unrest. Fortunately, the violent insurrection at the US Capitol on January 6, 2021, failed, and the inauguration of President Biden occurred two weeks later without incident. Since taking office, the Biden administration has initiated a host of federal policy changes affecting not only health but other areas of policy that relate to health, most notably environmental protection and climate change. Some of these policy shifts reverse Trump-era policies harmful to health, while others aim to improve or strengthen existing programs. Not surprisingly, many have aligned closely with ideas and recommendations contained in the 13 pieces posted thus far in the Building Back Better series. Because the administration continues to face formidable challenges that require timely, practical, evidence-based policy advice, we will continue the series for the foreseeable future and invite readers to visit our website (https://www.milbank.org/quarterly/ building-back-better/). The four Perspectives in this issue of the Quarterly all embrace the spirit of “building back better.” In “Population Health Science: Fulfilling the Mission of Public Health,” Frederick Zimmerman argues that public health has been distracted from its historical mission of ensuring the conditions in which people can be healthy. He attributes this to a heavy reliance on randomized controlled trials, a dearth of formal theoretical models, and a reluctance to engage in politics. However, he believes that the field of population health is bringing needed scientific tools to the aid of public health in fulfilling its core mission. Persistent communication inequities have limited the access of racial and ethnic minorities to life-saving health information, making them more vulnerable to the harmful effects of misinformation. In “The Com-
{"title":"In the March 2021 Issue of the Quarterly.","authors":"Alan B Cohen","doi":"10.1111/1468-0009.12512","DOIUrl":"https://doi.org/10.1111/1468-0009.12512","url":null,"abstract":"Since the launch of the Quarterly’s Building Back Better series of policy opinion posts in November 2020, the United States has experienced one of the most tumultuous and traumatic periods in its history. In fact, the entire year of 2020 will be remembered as a “perfect storm” of global pandemic, tragically avoidable death, reduced life expectancy, economic depression, racial injustice, and civil unrest. Fortunately, the violent insurrection at the US Capitol on January 6, 2021, failed, and the inauguration of President Biden occurred two weeks later without incident. Since taking office, the Biden administration has initiated a host of federal policy changes affecting not only health but other areas of policy that relate to health, most notably environmental protection and climate change. Some of these policy shifts reverse Trump-era policies harmful to health, while others aim to improve or strengthen existing programs. Not surprisingly, many have aligned closely with ideas and recommendations contained in the 13 pieces posted thus far in the Building Back Better series. Because the administration continues to face formidable challenges that require timely, practical, evidence-based policy advice, we will continue the series for the foreseeable future and invite readers to visit our website (https://www.milbank.org/quarterly/ building-back-better/). The four Perspectives in this issue of the Quarterly all embrace the spirit of “building back better.” In “Population Health Science: Fulfilling the Mission of Public Health,” Frederick Zimmerman argues that public health has been distracted from its historical mission of ensuring the conditions in which people can be healthy. He attributes this to a heavy reliance on randomized controlled trials, a dearth of formal theoretical models, and a reluctance to engage in politics. However, he believes that the field of population health is bringing needed scientific tools to the aid of public health in fulfilling its core mission. Persistent communication inequities have limited the access of racial and ethnic minorities to life-saving health information, making them more vulnerable to the harmful effects of misinformation. In “The Com-","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":" ","pages":"5-8"},"PeriodicalIF":6.6,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/1468-0009.12512","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25504957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality and Cost of Care by Hospital Teaching Status: What Are the Differences? 医院教学状况对护理质量和成本的影响:有何差异?
IF 6.6 Pub Date : 2021-03-01 DOI: 10.1111/1468-0009.12502
Frank A Sloan
<p><p>Policy Points In two respects, quality of care tends to be higher at major teaching hospitals: process of care and long-term survival of cancer patients following initial diagnosis. There is also evidence that short-term (30-day) mortality is lower on average at such hospitals, although the quality of evidence is somewhat lower. Quality of care is mulitdimensional. Empirical evidence by teaching status on dimensions other than survival is mixed. Higher Medicare payments for care provided by major teaching hospitals are partially offset by lower payments to nonhospital providers. Nevertheless, the payment differences between major teaching and nonteaching hospitals for hospital stays, especially for complex cases, potentially increase prices other insurers pay for hospital care.</p><p><strong>Context: </strong>The relative performance of teaching hospitals has been discussed for decades. For private and public insurers with provider networks, an issue is whether having a major teaching hospital in the network is a "must." For traditional fee-for-service Medicare, there is an issue of adequacy of payment of hospitals with various attributes, including graduate medical education (GME) provision. Much empirical evidence on relative quality and cost has been published. This paper aims to (1) evaluate empirical evidence on relative quality and cost of teaching hospitals and (2) assess what the findings indicate for public and private insurer policy.</p><p><strong>Methods: </strong>Complementary approaches were used to select studies for review. (1) Relevant studies highly cited in Web of Science were selected. (2) This search led to studies cited by these studies as well as studies that cited these studies. (3) Several literature reviews were helpful in locating pertinent studies. Some policy-oriented papers were found in Google under topics to which the policy applied. (4) Several papers were added based on suggestions of reviewers.</p><p><strong>Findings: </strong>Quality of care as measured in process of care studies and in longitudinal studies of long-term survival of cancer patients tends to be higher at major teaching hospitals. Evidence on survival at 30 days post admission for common conditions and procedures also tends to favor such hospitals. Findings on other dimensions of relative quality are mixed. Hospitals with a substantial commitment to graduate medical education, major teaching hospitals, are about 10% to 20% more costly than nonteaching hospitals. Private insurers pay a differential to major teaching hospitals at this range's lower end. Inclusive of subsidies, Medicare pays major teaching hospitals substantially more than 20% extra, especially for complex surgical procedures.</p><p><strong>Conclusions: </strong>Based on the evidence on quality, there is reason for patients to be willing to pay more for inclusion of major teaching hospitals in private insurer networks at least for some services. Medicare payment for GME has long
在两个方面,主要教学医院的护理质量往往更高:护理过程和癌症患者在初步诊断后的长期生存。也有证据表明,这些医院的短期(30天)死亡率平均较低,尽管证据的质量略低。护理质量是多方面的。除了生存之外,教学状况在其他方面的经验证据好坏参半。由主要教学医院提供的医疗保健的较高医疗保险支付部分被向非医院提供者支付的较低支付所抵消。然而,主要教学医院和非教学医院的住院费用差异,特别是复杂病例的住院费用差异,可能会增加其他保险公司为住院护理支付的费用。背景:教学医院的相对绩效已经被讨论了几十年。对于拥有供应商网络的私营和公共保险公司来说,一个问题是在网络中是否“必须”拥有一家大型教学医院。对于传统的按服务收费的医疗保险,存在着向具有各种属性的医院(包括提供研究生医学教育)支付充足费用的问题。许多关于相对质量和成本的经验证据已经发表。本文旨在(1)评估教学医院相对质量和成本的实证证据;(2)评估研究结果对公立和私营保险公司政策的启示。方法:采用互补方法选择研究进行综述。(1)选取Web of Science中被引频次较高的相关研究。(2)这项搜索产生了被这些研究引用的研究以及引用这些研究的研究。几篇文献综述有助于找到相关的研究。在谷歌中,在政策适用的主题下找到了一些政策导向的论文。(4)根据审稿人的建议,增加了几篇论文。研究结果:在护理过程研究和癌症患者长期生存的纵向研究中,主要教学医院的护理质量往往更高。入院后30天生存率的证据也倾向于这类医院。其他相对质量方面的调查结果好坏参半。有大量研究生医学教育的医院,主要的教学医院,比非教学医院的费用高10%到20%。私人保险公司在这个范围的低端向大型教学医院支付差额。包括补贴在内,医疗保险支付给大型教学医院的费用远远超过20%,尤其是复杂的外科手术。结论:基于质量方面的证据,患者有理由愿意为大型教学医院至少在某些服务上纳入私营保险公司网络而支付更多的费用。长期以来,医疗保险对中小企业的支付一直是一个有争议的政策问题。GME的实际间接成本可能远远低于医疗保险目前支付给医院的金额。
{"title":"Quality and Cost of Care by Hospital Teaching Status: What Are the Differences?","authors":"Frank A Sloan","doi":"10.1111/1468-0009.12502","DOIUrl":"https://doi.org/10.1111/1468-0009.12502","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Policy Points In two respects, quality of care tends to be higher at major teaching hospitals: process of care and long-term survival of cancer patients following initial diagnosis. There is also evidence that short-term (30-day) mortality is lower on average at such hospitals, although the quality of evidence is somewhat lower. Quality of care is mulitdimensional. Empirical evidence by teaching status on dimensions other than survival is mixed. Higher Medicare payments for care provided by major teaching hospitals are partially offset by lower payments to nonhospital providers. Nevertheless, the payment differences between major teaching and nonteaching hospitals for hospital stays, especially for complex cases, potentially increase prices other insurers pay for hospital care.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Context: &lt;/strong&gt;The relative performance of teaching hospitals has been discussed for decades. For private and public insurers with provider networks, an issue is whether having a major teaching hospital in the network is a \"must.\" For traditional fee-for-service Medicare, there is an issue of adequacy of payment of hospitals with various attributes, including graduate medical education (GME) provision. Much empirical evidence on relative quality and cost has been published. This paper aims to (1) evaluate empirical evidence on relative quality and cost of teaching hospitals and (2) assess what the findings indicate for public and private insurer policy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Complementary approaches were used to select studies for review. (1) Relevant studies highly cited in Web of Science were selected. (2) This search led to studies cited by these studies as well as studies that cited these studies. (3) Several literature reviews were helpful in locating pertinent studies. Some policy-oriented papers were found in Google under topics to which the policy applied. (4) Several papers were added based on suggestions of reviewers.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Quality of care as measured in process of care studies and in longitudinal studies of long-term survival of cancer patients tends to be higher at major teaching hospitals. Evidence on survival at 30 days post admission for common conditions and procedures also tends to favor such hospitals. Findings on other dimensions of relative quality are mixed. Hospitals with a substantial commitment to graduate medical education, major teaching hospitals, are about 10% to 20% more costly than nonteaching hospitals. Private insurers pay a differential to major teaching hospitals at this range's lower end. Inclusive of subsidies, Medicare pays major teaching hospitals substantially more than 20% extra, especially for complex surgical procedures.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Based on the evidence on quality, there is reason for patients to be willing to pay more for inclusion of major teaching hospitals in private insurer networks at least for some services. Medicare payment for GME has long","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":" ","pages":"273-327"},"PeriodicalIF":6.6,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/1468-0009.12502","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25504958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Population Health Science: Fulfilling the Mission of Public Health. 人口健康科学:履行公共卫生的使命。
IF 6.6 Pub Date : 2021-03-01 Epub Date: 2020-12-15 DOI: 10.1111/1468-0009.12493
Frederick J Zimmerman

Policy Points The historical mission of public health is to ensure the conditions in which people can be healthy, and yet the field of public health has been distracted from this mission by an excessive reliance on randomized-control trials, a lack of formal theoretical models, and a fear of politics. The field of population health science has emerged to rigorously address all of these constraints. It deserves ongoing and formal institutional support.

公共卫生的历史使命是确保人们能够保持健康的条件,然而,由于过度依赖随机对照试验、缺乏正式的理论模型以及对政治的恐惧,公共卫生领域偏离了这一使命。人口健康科学领域已经出现,以严格解决所有这些限制。它应该得到持续和正式的机构支持。
{"title":"Population Health Science: Fulfilling the Mission of Public Health.","authors":"Frederick J Zimmerman","doi":"10.1111/1468-0009.12493","DOIUrl":"https://doi.org/10.1111/1468-0009.12493","url":null,"abstract":"<p><p>Policy Points The historical mission of public health is to ensure the conditions in which people can be healthy, and yet the field of public health has been distracted from this mission by an excessive reliance on randomized-control trials, a lack of formal theoretical models, and a fear of politics. The field of population health science has emerged to rigorously address all of these constraints. It deserves ongoing and formal institutional support.</p>","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":" ","pages":"9-23"},"PeriodicalIF":6.6,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/1468-0009.12493","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38711635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Engaging Consumers in Medicaid Program Design: Strategies from the States. 参与医疗补助计划设计的消费者:来自各州的策略。
IF 6.6 Pub Date : 2021-03-01 Epub Date: 2020-12-15 DOI: 10.1111/1468-0009.12492
Jane M Zhu, Ruth Rowland, Rose Gunn, Sarah Gollust, David T Grande

Policy Points As Medicaid programs grow in scale and complexity, greater consumer input may guide successful program design, but little is known about the extent to which state agencies are engaging consumers in the design and implementation of programs and policies. Through 50 semistructured interviews with Medicaid leaders in 14 states, we found significant variation in consumer engagement approaches, with many common facilitators, including leadership commitment, flexible strategies for recruiting and supporting consumer participation, and robust community partnerships. We provide early evidence on how state Medicaid agencies are integrating consumers' experiences and perspectives into their program design and governance.

Context: Consumer engagement early in the process of health care policymaking may improve the effectiveness of program planning and implementation, promote patient-centric care, enhance beneficiary protections, and offer opportunities to improve service delivery. As Medicaid programs grow in scale and complexity, greater consumer input may guide successful program design, but little is known about the extent to which state agencies are currently engaging consumers in the design and implementation of programs and policies, and how this is being done.

Methods: We conducted semistructured interviews with 50 Medicaid program leaders across 14 states, employing a stratified purposive sampling method to select state Medicaid programs based on US census region, rurality, Medicaid enrollment size, total population, ACA expansion status, and Medicaid managed care penetration. Interview data were audio-recorded, professionally transcribed, and underwent iterative coding with content and thematic analyses.

Findings: First, we found variation in consumer engagement approaches, ranging from limited and largely symbolic interactions to longer-term deliberative bodies, with some states tailoring their federally mandated standing committees to engage consumers. Second, most states were motivated by pragmatic considerations, such as identifying and overcoming implementation challenges for agency programs. Third, states reported several common facilitators of successful consumer engagement efforts, including leadership commitment, flexible strategies for recruiting and supporting consumers' participation, and robust community partnerships. All states faced barriers to authentic and sustained engagement.

Conclusions: Sharing best practices across states could help strengthen programs' engagement efforts, identify opportunities for program improvement reflecting community needs, and increase participation among a population that has traditionally lacked a political voice.

随着医疗补助计划的规模和复杂性不断扩大,更多的消费者投入可能会指导成功的计划设计,但人们对州政府机构在计划和政策的设计和实施中让消费者参与的程度知之甚少。通过对14个州的医疗补助领导者进行50次半结构化访谈,我们发现消费者参与方法存在显著差异,有许多共同的促进因素,包括领导承诺,招聘和支持消费者参与的灵活策略,以及强大的社区伙伴关系。我们提供了关于州医疗补助机构如何将消费者的经验和观点纳入其计划设计和治理的早期证据。背景:在医疗保健政策制定过程的早期,消费者的参与可以提高方案规划和实施的有效性,促进以患者为中心的护理,加强对受益人的保护,并提供改善服务提供的机会。随着医疗补助计划的规模和复杂性不断扩大,更多的消费者投入可能会指导成功的计划设计,但人们对州政府机构目前在多大程度上让消费者参与到计划和政策的设计和实施中,以及如何做到这一点知之甚少。方法:我们对来自14个州的50位医疗补助计划负责人进行了半结构化访谈,采用分层有目的抽样方法,根据美国人口普查地区、农村、医疗补助登记规模、总人口、ACA扩张状况和医疗补助管理医疗普及率选择州医疗补助计划。采访数据录音,专业转录,并进行内容和主题分析的迭代编码。研究发现:首先,我们发现消费者参与方式存在差异,从有限的、主要是象征性的互动到长期的审议机构,一些州调整了联邦授权的常设委员会,以吸引消费者。其次,大多数州的动机是出于务实的考虑,例如确定和克服机构项目的实施挑战。第三,各州报告了成功的消费者参与努力的几个共同促进因素,包括领导承诺,招募和支持消费者参与的灵活战略,以及强有力的社区伙伴关系。所有国家都面临着真正和持续接触的障碍。结论:在各州之间分享最佳实践有助于加强项目的参与力度,发现反映社区需求的项目改进机会,并提高传统上缺乏政治发言权的人群的参与度。
{"title":"Engaging Consumers in Medicaid Program Design: Strategies from the States.","authors":"Jane M Zhu,&nbsp;Ruth Rowland,&nbsp;Rose Gunn,&nbsp;Sarah Gollust,&nbsp;David T Grande","doi":"10.1111/1468-0009.12492","DOIUrl":"https://doi.org/10.1111/1468-0009.12492","url":null,"abstract":"<p><p>Policy Points As Medicaid programs grow in scale and complexity, greater consumer input may guide successful program design, but little is known about the extent to which state agencies are engaging consumers in the design and implementation of programs and policies. Through 50 semistructured interviews with Medicaid leaders in 14 states, we found significant variation in consumer engagement approaches, with many common facilitators, including leadership commitment, flexible strategies for recruiting and supporting consumer participation, and robust community partnerships. We provide early evidence on how state Medicaid agencies are integrating consumers' experiences and perspectives into their program design and governance.</p><p><strong>Context: </strong>Consumer engagement early in the process of health care policymaking may improve the effectiveness of program planning and implementation, promote patient-centric care, enhance beneficiary protections, and offer opportunities to improve service delivery. As Medicaid programs grow in scale and complexity, greater consumer input may guide successful program design, but little is known about the extent to which state agencies are currently engaging consumers in the design and implementation of programs and policies, and how this is being done.</p><p><strong>Methods: </strong>We conducted semistructured interviews with 50 Medicaid program leaders across 14 states, employing a stratified purposive sampling method to select state Medicaid programs based on US census region, rurality, Medicaid enrollment size, total population, ACA expansion status, and Medicaid managed care penetration. Interview data were audio-recorded, professionally transcribed, and underwent iterative coding with content and thematic analyses.</p><p><strong>Findings: </strong>First, we found variation in consumer engagement approaches, ranging from limited and largely symbolic interactions to longer-term deliberative bodies, with some states tailoring their federally mandated standing committees to engage consumers. Second, most states were motivated by pragmatic considerations, such as identifying and overcoming implementation challenges for agency programs. Third, states reported several common facilitators of successful consumer engagement efforts, including leadership commitment, flexible strategies for recruiting and supporting consumers' participation, and robust community partnerships. All states faced barriers to authentic and sustained engagement.</p><p><strong>Conclusions: </strong>Sharing best practices across states could help strengthen programs' engagement efforts, identify opportunities for program improvement reflecting community needs, and increase participation among a population that has traditionally lacked a political voice.</p>","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":" ","pages":"99-125"},"PeriodicalIF":6.6,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/1468-0009.12492","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38711636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
In the September 2020 Issue of the Quarterly. 《季刊》2020年9月号。
IF 6.6 Pub Date : 2020-09-01 DOI: 10.1111/1468-0009.12478
TheCOVID-19 pandemic remains in full swing across the globe, with the death toll mounting steadily while the search continues for effective vaccines and therapeutics to combat it. Few have been untouched by the epidemic’s rampage—whether having survived its deadly grip, suffered the loss of a loved one, lost one’s source of income, or simply had one’s life turned upside down by the restrictions put in place to stem its spread. COVID-19 pervasively rules the daily news cycle, dominates our thoughts and conversations, and dictates new norms of behavior that challenge and perhaps, at times, rankle our sensibilities. How long it will last is anyone’s guess. Recently, we issued a call for papers about health beyond COVID in three broad areas: improving population health; improving public health infrastructure; and improving health care. Thus far, we have been pleased to receive several thoughtful commentaries and original research articles in all three areas that will directly inform policymakers and policymaking in health and social sectors. The call for papers (https://www.milbank.org/quarterly/call-for-papers/) remains open through December 31, 2020. This issue of the Quarterly opens with two insightful Perspectives related to population health. In “Population Health in the Time of COVID-19: Confirmations and Revelations,” Ana Diez Roux reflects upon the clinical, epidemiologic, and social factors that drive the many visible manifestations of the pandemic in the population. She observes that the pandemic has revealed how we as a society have acted (or have failed to act) to protect our health, and she discusses the challenges and implications for the future, including how the pandemic may yield unanticipated opportunities for population health. She offers several suggestions for how we can change the way we live and how we may create systems and environments that promote health and health equity. In “Well-Being in the Nation: A Living Library of Measures to Drive Multisector Population Health Improvement and Address Social Determinants,” Somava Saha and colleagues describe how the 100 Million Healthier Lives framework facilitated a multisector collaboration to
{"title":"In the September 2020 Issue of the Quarterly.","authors":"","doi":"10.1111/1468-0009.12478","DOIUrl":"https://doi.org/10.1111/1468-0009.12478","url":null,"abstract":"TheCOVID-19 pandemic remains in full swing across the globe, with the death toll mounting steadily while the search continues for effective vaccines and therapeutics to combat it. Few have been untouched by the epidemic’s rampage—whether having survived its deadly grip, suffered the loss of a loved one, lost one’s source of income, or simply had one’s life turned upside down by the restrictions put in place to stem its spread. COVID-19 pervasively rules the daily news cycle, dominates our thoughts and conversations, and dictates new norms of behavior that challenge and perhaps, at times, rankle our sensibilities. How long it will last is anyone’s guess. Recently, we issued a call for papers about health beyond COVID in three broad areas: improving population health; improving public health infrastructure; and improving health care. Thus far, we have been pleased to receive several thoughtful commentaries and original research articles in all three areas that will directly inform policymakers and policymaking in health and social sectors. The call for papers (https://www.milbank.org/quarterly/call-for-papers/) remains open through December 31, 2020. This issue of the Quarterly opens with two insightful Perspectives related to population health. In “Population Health in the Time of COVID-19: Confirmations and Revelations,” Ana Diez Roux reflects upon the clinical, epidemiologic, and social factors that drive the many visible manifestations of the pandemic in the population. She observes that the pandemic has revealed how we as a society have acted (or have failed to act) to protect our health, and she discusses the challenges and implications for the future, including how the pandemic may yield unanticipated opportunities for population health. She offers several suggestions for how we can change the way we live and how we may create systems and environments that promote health and health equity. In “Well-Being in the Nation: A Living Library of Measures to Drive Multisector Population Health Improvement and Address Social Determinants,” Somava Saha and colleagues describe how the 100 Million Healthier Lives framework facilitated a multisector collaboration to","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":" ","pages":"623-628"},"PeriodicalIF":6.6,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/1468-0009.12478","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38364726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Out-of-Network Air Ambulance Bills: Prevalence, Magnitude, and Policy Solutions. 网络外空中救护费用:流行程度、规模和政策解决方案。
IF 6.6 Pub Date : 2020-09-01 Epub Date: 2020-06-11 DOI: 10.1111/1468-0009.12464
Erin C Fuse Brown, Erin Trish, Bich Ly, Mark Hall, Loren Adler
<p><p>Policy Points Out-of-network air ambulance bills are a type of surprise medical bill and are driven by many of the same market failures behind other surprise medical bills, including patients' inability to choose in-network providers in an emergency or to avoid potential balance billing by out-of-network providers. The financial risk to consumers is high because more than three-quarters of air ambulances are out-of-network and their prices are high and rising. Consumers facing out-of-network air ambulance bills have few legal protections owing to the Airline Deregulation Act's federal preemption of state laws. Any federal policies for surprise medical bills should also address surprise air ambulance bills and should incorporate substantive consumer protections-not just billing transparency-and correct the market distortions for air ambulances.</p><p><strong>Context: </strong>Out-of-network air ambulance bills are a growing problem for consumers. Because most air ambulance transports are out-of-network and prices are rising, patients are at risk of receiving large unexpected bills. This article estimates the prevalence and magnitude of privately insured persons' out-of-network air ambulance bills, describes the legal barriers to curtailing surprise air ambulance bills, and proposes policies to protect consumers from out-of-network air ambulance bills.</p><p><strong>Methods: </strong>We used the Health Care Cost Institute's 2014-2017 data from three large national insurers to evaluate the share of air ambulance claims that are out-of-network and the prevalence and magnitude of potential surprise balance bills, focusing on rotary-wing transports. We estimated the magnitude of potential balance bills for out-of-network air ambulance services by calculating the difference between the provider's billed charges and the insurer's out-of-network allowed amount, including the patient's cost-sharing. For in-network air ambulance transports, we calculated the average charges and allowed amounts, both in absolute magnitude and as a multiple of the rate that Medicare pays for the same service.</p><p><strong>Findings: </strong>We found that less than one-quarter of air ambulance transports of commercially insured patients were in-network. Two-in-five transports resulted in a potential balance bill, averaging $19,851. In the latter years of our data, in-network rates for transports by independent (non-hospital-based) carriers averaged $20,822, or 369% of the Medicare rate for the same service.</p><p><strong>Conclusions: </strong>Because the states' efforts to curtail air ambulance balance billing have been preempted by the Airline Deregulation Act, a federal solution is needed. Owing to the failure of market forces to discipline either prices or supply, out-of-network air ambulance rates should be benchmarked to a multiple of Medicare rates or, alternatively, air ambulance services could be delivered and financed through an approach that combines competiti
网络外空中救护账单是一种意外医疗账单,它是由其他意外医疗账单背后的许多相同的市场失灵驱动的,包括患者在紧急情况下无法选择网络内提供者或避免网络外提供者潜在的余额账单。消费者面临的财务风险很高,因为超过四分之三的空中救护车不在网络范围内,价格很高,而且还在上涨。由于《航空公司放松管制法案》的联邦法律优先于州法律,面临网络外空中救护费用的消费者几乎没有法律保护。任何针对意外医疗账单的联邦政策都应该考虑意外空中救护账单,并应纳入实质性的消费者保护——而不仅仅是账单透明度——并纠正空中救护的市场扭曲。背景:网络外空中救护费用对消费者来说是一个日益严重的问题。由于大多数空中救护运输都在网络之外,价格也在上涨,病人面临着收到大笔意外账单的风险。本文估计了私人参保人员网外空中救护费用的普遍程度和规模,描述了限制意外空中救护费用的法律障碍,并提出了保护消费者免受网外空中救护费用影响的政策。方法:我们使用卫生保健成本研究所2014-2017年来自三家大型国家保险公司的数据来评估网络外空中救护索赔的份额以及潜在意外余额账单的患病率和规模,重点是旋翼运输。我们通过计算医疗服务提供者的账单费用和保险公司的网络外允许金额(包括患者的费用分摊)之间的差额,估计了网络外空中救护服务的潜在账单余额的大小。对于网络内的空中救护运输,我们计算了平均费用和允许的金额,包括绝对值和医疗保险为相同服务支付的费率的倍数。研究结果:我们发现只有不到四分之一的商业保险患者的空中救护运输是在网络内。五分之二的交通导致了潜在的账单余额,平均为19,851美元。在我们最近几年的数据中,独立(非医院)运营商的网络内运输费用平均为20,822美元,相当于相同服务的医疗保险费用的369%。结论:由于各州削减空中救护平衡账单的努力已经被航空放松管制法案所取代,因此需要联邦政府的解决方案。由于市场力量无法约束价格或供应,网络外空中救护费率应以医疗保险费率的数倍为基准,或者,空中救护服务可以通过竞争性招标和公用事业监管相结合的方式提供和融资。
{"title":"Out-of-Network Air Ambulance Bills: Prevalence, Magnitude, and Policy Solutions.","authors":"Erin C Fuse Brown,&nbsp;Erin Trish,&nbsp;Bich Ly,&nbsp;Mark Hall,&nbsp;Loren Adler","doi":"10.1111/1468-0009.12464","DOIUrl":"https://doi.org/10.1111/1468-0009.12464","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Policy Points Out-of-network air ambulance bills are a type of surprise medical bill and are driven by many of the same market failures behind other surprise medical bills, including patients' inability to choose in-network providers in an emergency or to avoid potential balance billing by out-of-network providers. The financial risk to consumers is high because more than three-quarters of air ambulances are out-of-network and their prices are high and rising. Consumers facing out-of-network air ambulance bills have few legal protections owing to the Airline Deregulation Act's federal preemption of state laws. Any federal policies for surprise medical bills should also address surprise air ambulance bills and should incorporate substantive consumer protections-not just billing transparency-and correct the market distortions for air ambulances.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Context: &lt;/strong&gt;Out-of-network air ambulance bills are a growing problem for consumers. Because most air ambulance transports are out-of-network and prices are rising, patients are at risk of receiving large unexpected bills. This article estimates the prevalence and magnitude of privately insured persons' out-of-network air ambulance bills, describes the legal barriers to curtailing surprise air ambulance bills, and proposes policies to protect consumers from out-of-network air ambulance bills.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We used the Health Care Cost Institute's 2014-2017 data from three large national insurers to evaluate the share of air ambulance claims that are out-of-network and the prevalence and magnitude of potential surprise balance bills, focusing on rotary-wing transports. We estimated the magnitude of potential balance bills for out-of-network air ambulance services by calculating the difference between the provider's billed charges and the insurer's out-of-network allowed amount, including the patient's cost-sharing. For in-network air ambulance transports, we calculated the average charges and allowed amounts, both in absolute magnitude and as a multiple of the rate that Medicare pays for the same service.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;We found that less than one-quarter of air ambulance transports of commercially insured patients were in-network. Two-in-five transports resulted in a potential balance bill, averaging $19,851. In the latter years of our data, in-network rates for transports by independent (non-hospital-based) carriers averaged $20,822, or 369% of the Medicare rate for the same service.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Because the states' efforts to curtail air ambulance balance billing have been preempted by the Airline Deregulation Act, a federal solution is needed. Owing to the failure of market forces to discipline either prices or supply, out-of-network air ambulance rates should be benchmarked to a multiple of Medicare rates or, alternatively, air ambulance services could be delivered and financed through an approach that combines competiti","PeriodicalId":501846,"journal":{"name":"The Milbank Quarterly","volume":" ","pages":"747-774"},"PeriodicalIF":6.6,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/1468-0009.12464","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38033466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
期刊
The Milbank Quarterly
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1